Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 1:6:1928.
doi: 10.12688/f1000research.11545.1. eCollection 2017.

Autoimmune lymphoproliferative syndrome: more than a FAScinating disease

Karen Bride  1 , David Teachey  1
Affiliations
Review

Autoimmune lymphoproliferative syndrome: more than a FAScinating disease

Karen Bride et al. F1000Res. .

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is an inherited syndrome characterized by abnormal lymphocyte survival caused by failure of apoptotic mechanisms to maintain lymphocyte homeostasis. This failure leads to the clinical manifestations of non-infectious and non-malignant lymphadenopathy, splenomegaly, and autoimmune pathology, most commonly, autoimmune cytopenias. Since ALPS was first characterized in the early 1990s, insights in disease biology have improved both diagnosis and management of this syndrome. Sirolimus is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients in need of chronic treatment. This review highlights practical clinical considerations for the diagnosis and management of ALPS. Further studies could reveal new proteins and regulatory pathways that are critical for lymphocyte activation and apoptosis.

Keywords: Fas/FasL; MMF; Targeted therapy; autoimmune; cytopenias; double negative T cells; lymphoproliferative disease; sirolimus.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Fas apoptotic pathway.
In an attempt to downregulate an immune response, activated B and T cells upregulate FAS while activated T cells will activate FAS ligand (FASL). These cells will interact and trigger a caspase cascade, leading to proteolysis, DNA degradation, and apoptosis. This FAS-mediated pathway is part of the extrinsic apoptotic pathway. In contrast, mitochondrial-induced apoptosis after cellular stress is part of the intrinsic apoptotic pathway.
Figure 2.
Figure 2.. Proposed algorithm of our approach to the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS) and associated mild-moderate and moderate-severe autoimmune disease, with or without clinically significant lymphoproliferation.
Adapted from George et al. . BID, twice daily.
See this image and copyright information in PMC

References

    1. George LA, Teachey DT: Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children. Paediatr Drugs. 2016;18(4):261–72. 10.1007/s40272-016-0175-3 - DOI - PMC - PubMed
    1. Oliveira JB, Bleesing JJ, Dianzani U, et al. : Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–40. 10.1182/blood-2010-04-280347 - DOI - PMC - PubMed
    1. Teachey DT: Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management. Clin Adv Hematol Oncol. 2011;9(3):233–5. - PubMed
    1. Teachey DT: New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr. 2012;24(1):1–8. 10.1097/MOP.0b013e32834ea739 - DOI - PMC - PubMed
    1. Tarbox JA, Keppel MP, Topcagic N, et al. : Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34(5):594–9. 10.1007/s10875-014-0038-z - DOI - PMC - PubMed